

## Curriculum Vitae Enno Schmidt

### Personal Data

Title	Prof. Dr. med. Dr. rer. nat.
First name	<b>Enno</b>
Name	<b>Schmidt</b>
Current position	Professor and Director (permanent)
Current institution(s)/site(s), country	Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany
Identifiers/ORCID	000-0002-1206-8913

### Selection of peer-reviewed research articles:

- Goletz, S, Pigors, M, Lari, *et int*, **Schmidt, E**. Laminin beta4 is a constituent of the cutaneous basement membrane zone and additional autoantigen of anti-p200 pemphigoid. *J Am Acad Dermatol*. 2024 Apr;90(4): 790-797. doi: 10.1016/j.jaad.2023.11.014.
- van Beek, N, Eming, R, Reuss, A, *et int*, **Schmidt, E**. Efficacy and safety of adjuvant immunoabsorption in pemphigus vulgaris and pemphigus foliaceus (IA-Pem Study): a multicentre randomized controlled trial. *Br J Dermatol*. 2024 Apr 17;190(5): 657-667. doi: 10.1093/bjd/ljad489.
- Pigors, M, Patzelt, S, Reichhelm, N, *et int*, **Schmidt, E**. Bullous pemphigoid induced by IgG targeting type XVII collagen non-NC16A/NC15A extracellular domains is driven by Fc gamma receptor- and complement-mediated effector mechanisms and is ameliorated by neonatal Fc receptor blockade. *J Pathol* 2024 Feb;262(2): 161-174. doi: 10.1002/path.6220.
- Franz, H, Rathod, M, Zimmermann, A, *et int*, **Schmidt, E**, Spindler, V. Unbiased screening identifies regulators of cell-cell adhesion and treatment options in pemphigus. *Nat Commun*. 2024 Sep 14;15(1): 8044. doi: 10.1038/s41467-024-51747-2.
- van Beek, N, Kridin, K, Buhler, E, *et int*, **Schmidt, E**, Gunther, C. Evaluation of Site- and Autoantigen-Specific Characteristics of Mucous Membrane Pemphigoid. *JAMA Dermatol*. 2022 Jan 1;158(1): 84-89. doi: 10.1001/jamadermatol.2021.4773.
- Schmidt, E**, Kasperkiewicz, M, Joly, P. Pemphigus. *Lancet* 2019 Sep 7;394(10201): 882-894. doi: 10.1016/S0140-6736(19)31778-7.
- Chakievska, L, Holtsche, MM, Kunstner, A, *et int*, **Schmidt, E**. IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid. *J Autoimmun*. 2019 Jan;96(104-112). doi: 10.1016/j.jaut.2018.09.003.
- Schmidt, E**. Rituximab as first-line treatment of pemphigus. *Lancet* 2017 May 20;389(10083): 1956-1958. doi: 10.1016/S0140-6736(17)30787-0.
- Heppe, EN, Tofern, S, Schulze, FS, *et int*, **Schmidt, E**. Experimental Laminin 332 Mucous Membrane Pemphigoid Critically Involves C5aR1 and Reflects Clinical and Immunopathological Characteristics of the Human Disease. *J Invest Dermatol* 2017 Aug;137(8): 1709-1718. doi: 10.1016/j.jid.2017.03.037.
- Schmidt, E**, Zillikens, D. Pemphigoid diseases. *Lancet* 2013 Jan 26;381(9863): 320-32. doi: S0140-6736(12)61140-4.